Lessons of the pandemic loom large in EU’s pharmaceutical strategy. ‘Never again do we want to see the problems we faced in the first weeks of the crisis,’ says EU vice president Margaritis Schinas
The Innovative Health Initiative will see the scope of joint research between industry, academics and SMEs expand beyond pharmaceuticals, to include medical technology, biotech, digital health and vaccines
UK medicines regulator seeks to allay pharma industry concern, reiterating a previous promise it will be pragmatic in setting new UK drugs rules in event of no-deal Brexit
Industry says failure to consider new ways of assessing the value of drugs, including outcomes-based approaches and the use of real world evidence, represents a missed opportunity to promote sustainability of Europe’s healthcare systems